StockData
ABVC BioPharma, Inc. logo

ABVC BioPharma, Inc. (ABVC) shareholders

ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.94+0.03 (+3.30%)

Close on Nov 16, 2026Market cap $25.06MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
1M
Shares held, 13F filers
Institutional holders
15
7 new, 5 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Lind Global Fund II LP
Joint filing with Lind Global Partners II LLC (9.90%), Easton Jeff (9.90%)
1,325,0009.90%13G (passive) amendmentDec 31, 2024
Eugene Jiang131,15918.50%13D (active) amendmentJul 10, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ABVCValueChange% of portfolio
Vanguard Capital Management LLC374,499–$591.71K+183,9250.00%
Geode Capital Management, LLC228,042–$360.38K+6,8730.00%
Vanguard Fiduciary Trust Co97,363–$153.83K–0.00%
State Street Corp72,800–$115.02K–0.00%
Citadel Advisors LLC72,091–$113.90KNew0.00%
BlackRock, Inc.56,442–$89.18K–0.00%
Northern Trust Corp48,643–$76.86K+16,5560.00%
XTX Topco Ltd48,276–$76.28KNew0.00%
Panagora Asset Management Inc36,682–$57.96KNew0.00%
UBS Group AG34,123–$53.91K+32,3520.00%
Jane Street Group, LLC20,059–$31.69KNew0.00%
Citigroup Inc540–$853New0.00%
LifeSteps Financial, Inc.300–$474New0.00%
Royal Bank of Canada17–$0–0.00%
Caitong International Asset Management Co., Ltd6–$9New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 2026151M7 / 40 / 50M0M
Q1 2026131M6 / 22 / 60M0M
Q4 2025141M2 / 82 / 20M0M
Q3 2025141M6 / 62 / 10M0M
Q2 202590M1 / 52 / 20M0M
Q1 2025100M0 / 52 / 30M0M
Q4 2024130M4 / 51 / 00M0M
Q3 202490M1 / 22 / 20M0M
Q2 2024110M5 / 21 / 20M0M
Q1 202480M2 / 40 / 20M0M
Q4 202380M1 / 31 / 20M0M
Q3 202390M9 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

7 funds held ABVC in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ABVCValue% of fundAs of
Vanguard Extended Market Index Fund208,279–$329.08K0.00%Jun 30, 2026
Vanguard Total Stock Market Index Fund115,243–$182.08K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund109,835–$154.87K0.00%May 31, 2026
Fidelity Total Market Index Fund31,053–$43.78K0.00%May 31, 2026
Fidelity Series Total Market Index Fund28,657–$40.41K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund6,128–$8.64K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-100–-$158-0.00%Jun 30, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Kevin Patrick Stolz
VP & Controller
Jan 27, 2012Award+6,250––6,250
Joseph Nirta
Director
May 11, 2010Buy+10,000$0.15$1.50K10,000
Joseph Nirta
Director
Mar 22, 2010Buy+2,000$0.26$5202,000
J.B. Smith
Director, 10% owner
Nov 13, 2009Buy+714,286$50000.00$35.71B16,585,538
Daniel V. Iannotti
VP, General Counsel & Secretar
Sep 21, 2009Award+70,000$0.51$35.70K400,000
Frank Thomas Krotine
President & COO
Sep 21, 2009Award+169,000$0.51$86.19K510,217
Robert G. Crockett
Chief Executive Officer
Sep 21, 2009Award+670,000$0.51$341.70K1,000,000
J.B. Smith
Director, 10% owner
Aug 31, 2009Buy+192,308$50000.00$9.62B18,430,752
J.B. Smith
Director, 10% owner
Aug 31, 2009Buy+192,308$50000.00$9.62B17,349,752
J.B. Smith
Director, 10% owner
Aug 19, 2009Gift−300,000––17,575,000
J.B. Smith
Director, 10% owner
Jun 10, 2009Buy+20$20000.00$400.00K336
J.B. Smith
Director, 10% owner
Jun 2, 2009Buy+55$55000.00$3.03M2,436
J.B. Smith
Director, 10% owner
Jun 2, 2009Buy+40$40000.00$1.60M316
J.B. Smith
Director, 10% owner
Apr 29, 2009Buy+34$34000.00$1.16M2,381
J.B. Smith
Director, 10% owner
Apr 14, 2009Buy+21$21000.00$441.00K2,347
J.B. Smith
Director, 10% owner
Mar 26, 2009Buy+80$80000.00$6.40M2,326
Sally Judith Ramsey
Director, 10% owner
Mar 26, 2009Buy+80$80000.00$6.40M2,326
J.B. Smith
Director, 10% owner
Mar 10, 2009Buy+23$23000.00$529.00K2,246
J.B. Smith
Director, 10% owner
Feb 26, 2009Buy+40$40000.00$1.60M2,223
J.B. Smith
Director, 10% owner
Feb 11, 2009Buy+30$30000.00$900.00K2,158
J.B. Smith
Director, 10% owner
Feb 10, 2009Other+24––2,128
Richard Dean Stromback
Director, 10% owner
Jan 23, 2009Sale−4,000,000$1.00$4.00M10,637,500
J.B. Smith
Director, 10% owner
Jan 23, 2009Buy+4,000,000––5,500,000
Richard Dean Stromback
Director, 10% owner
Jan 23, 2009Sale−4,000,000$1.00$4.00M10,637,500
J.B. Smith
Director, 10% owner
Jan 23, 2009Buy+4,000,000$1.00$4.00M5,500,000
J.B. Smith
Director
Sep 26, 2008Buy+750$1000.00$750.00K2,010
Richard Dean Stromback
CEO, Director, 10% owner
Aug 18, 2008Sale−1,500,000––14,637,500
Sally Judith Ramsey
VP New Product Development
Jul 30, 2007Buy+3,000,000––3,000,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
19.9
At 0M shares a day
Change since last report
+2.2%
From 1M shares
Short volume, 20 days
20.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ABVC BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,136 shares on Sep 3, 2026 over the last 90 days.

See a number that looks wrong?